JSH consensus Kobe 2009; Diagnosis and treatment of NASH

Kanzo/Acta Hepatologica Japonica

Volumn 50, Issue 12, 2009, Pages 741-747

  Okanoue, Takeshi ^a   Saibara, Toshiji ^b   Ono, Masafumi ^b   Sumida, Yoshio ^c   Hashimoto, Etsuko ^d   Tamura, Shinji ^e   Yamada, Gotaro ^f   Kawada, Sumio ^g   Kudo, Masatoshi ^h  

^a Saiseikai Suita Hospital   (Japan)

^b KOCHI UNIVERSITY   (Japan)

^c Nara City Hospital   (Japan)

^d TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^e Mino City Hospital   (Japan)

^f Kawasaki Medical University Kawasaki Hospital   (Japan)

^g YAMAGATA UNIVERSITY   (Japan)

^h KINKI UNIVERSITY   (Japan)

Author keywords

Hepatocellular carcinoma; Insulin resistance; Liver cirrhosis; Metabolic syndrome; Oxidative stress

Indexed keywords

ARTICLE; CONSENSUS; INSULIN RESISTANCE; JAPANESE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS;

EID: 76549136235     PISSN: 04514203     EISSN: None     Source Type: Journal    
DOI: 10.2957/kanzo.50.741     Document Type: Article

References (31)

1. Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clinic Proceedings 1980; 55: 434-488
2. Schaffner F. Thaler H. Nonalcoholic fatty liver disease. Progress in Liver Disease 1986; 8: 283-298
3. Wanless IR. Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-1110
4. [NASH · NAFLD], 2006, p30-31
5. Ono M, Saibara T. Clinical features of nonalcoholic steatohepatitis in Japan: Evidence from the literature. Journal of Gastroenterology 2006; 41: 725-732
6. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1705-1725
7. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419
8. Rafiq N, Bai C, Fang Y, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clinical Gastroenterol Hepatol 2009; 7: 234-238
9. Murata Y, Ogawa Y, Saibara T, et al. Tamoxifen-induced non-alcoholic steatohepatitis in patients with breast cancer: determination of a suitable biopsy site for diagnosis. Oncol Rep 2003; 10: 97-100
10. Merriman RB, Ferrell LD, Patti MG, et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 2006; 44: 874-880
11. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fattyliver disease. Hepatology 2005: 41: 1313-1321
12. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference, Hepatology 2003; 37: 1202-1219
13. Farrell GC, Chitturi S, Lau GK, et al; Asia-Pacific Working Party on NAFLD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region. J Gastroenterol Hepatol 2007; 22: 775-777
14. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-854
15. Harrison SA, Oliver D, Arnold HL, et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57: 1441-1447
16. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple marker. Hepatology 2008; 47: 445-460
17. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009; 49: 306-317
18. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395
19. Dong H, Wang J, Li C, et al. The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population. J Hepatol 2007; 46: 91-920
20. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461-1465
21. Sumida Y, Nakashima T, Yoh T, et al. Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease. J Hepatol 2003; 38: 32-38
22. Ikura Y, Ohsawa M, Suekane T, et al. Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: impact on disease progression. Hepatology 2006; 43: 506-514
23. Diehl AM, Li ZP, Lin HZ, et al. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 2005; 54: 303-306
24. Hui JM, Hodge A, Farrell GC, et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004; 40: 46-54
25. Teli MR, James OF, Burt AD, et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 22: 1714-1719
26. Fassio E, Alvarez E, Dominguez N, et al. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004; 40: 820-826
27. Adams LA, Sanderson S, Lindor KD, et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005; 42: 132-138
28. Ekstedt M, Franz L E, Mathiesen U L, et al. Long-Term Follow-up of Patients With NAFLD and Elevated Liver Enzymes. Hepatology 2006; 44: 865-873
29. Shimada M, Hashimoto E, Taniai M, et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepabtis. J Hepatol 2002; 37: 154-160
30. Mummadi RR, Kasturi KS, Chennareddygani S, et al. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2008; 6: 1396-1402
31. Anderson N, Borlak J, Molecular Mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol Rev 2008; 60: 311-357